serpin family B member 4Genealiases: LEUPIN · PI11 · SCCA-2 · SCCA1 · SCCA2
Q-omics provides the consensus-scored SERPINB4 profile across patient tissues and cancer cell-line models. SERPINB4 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SERPINB4 is differentially expressed in 4, with the highest sampling consensus in LUAD. Additionally, SERPINB4 protein abundance shows 10,152 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight KIRC, LUAD, and HNSC as cancer lineages where SERPINB4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SERPINB4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SERPINB4 survival associations across molecular data types. SERPINB4 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SERPINB4 RNA expression–survival associations across cancer types. High SERPINB4 expression shows unfavorable associations in KIRC, LUAD, STAD, OV, KIRP and LIHC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SERPINB4 RNA expression.
This table summarizes SERPINB4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4, while mass-spec protein shows differences in 3. The strongest signals are observed in LUAD for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for SERPINB4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SERPINB4 shows higher tumor expression in LUAD, LUSC, THCA and BLCA. The LUAD box plot shows higher SERPINB4 RNA expression in tumor versus normal tissue (log2 FC = +1.112, t-test p < 0.001).
This table shows molecular features associated with SERPINB4 in patient tissues and cancer cell lines. In patient samples, SERPINB4 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, SERPINB4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Myeloma.
